Concepedia

Matt D. Galsky

MD

Statistics

Publications

58

Citations

1.7K

H-Index

24

Active since

2004

Affiliations

Icahn School of Medicine at Mount Sinai(Current)

Tisch Cancer Institute

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Fondazione IRCCS Istituto Nazionale dei Tumori

Matt D. Galsky is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, oncology, and chemotherapy.

Publications per year

2004–2025

58

Publications

58

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Guru Sonpavde, John M. Burke, J. R. Caton et al. · Annals of Oncology · 2011 · 143 citations

, , +16

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

Guru Sonpavde, Andrea Necchi, Shilpa Gupta et al. · Future Oncology · 2019 · 92 citations · Full text

, , +17

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

Padmanee Sharma, Russell K. Pachynski, Vivek Narayan et al. · Journal of Clinical Oncology · 2019 · 91 citations

, , +17

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

, , +17

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

Scott T. Tagawa, Bishoy M. Faltas, Elaine T. Lam et al. · Journal of Clinical Oncology · 2019 · 84 citations

, , +17

1–5 of 58